| abstract |
An oral dosage form of a compound selected from boronic acids which have a neutral thrombin (P1) domain linked to a hydrophobic moiety capable of binding to the thrombin (S2) and (S3) subsites, and salts, prodrugs and prodrug salts of such acids, the dosage form comprising a solid phase formulation comprising the compound and being adapted for reconstitution of the formulation to form a liquid preparation. |